Phase 2 N=8 Poststroke Depression in Hemorrhagic Stroke
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial
Subarachnoid Hemorrhage, Aneurysmal · Delayed Cerebral Ischemia · Vasospasm, Cerebral
Primary: Participants With Adverse Events — 2; 0; 0; 0 Participants
Phase 4 N=16 Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Primary: Average Numeric Pain Score — 5.2; 5.8 score on a scale — p=0.7
Phase 2 N=30 Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
Subarachnoid Hemorrhage, Aneurysmal
Primary: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) — 2; 1 Participants
Phase 2 N=31 Safety Study of Dantrolene in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage · Cerebral Vasospasm
Primary: Hyponatremia — 7; 10 participants
Phase 2 N=42 Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
Subarachnoid Hemorrhage
Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min
Phase 2 N=30 Subarachnoid Hemorrhage Recovery And Galantamine
Subarachnoid Hemorrhage
Primary: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug — 1; 1 Participants
N/A N=33 FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension
Subarachnoid Hemorrhage
Primary: Mean Change in Cisternal Blood From Enrollment to Catheter Removal — -64.7 percent change
N/A N=37 Ventriculostomies in SAH: ICP Open or Not?
Subarachnoid Hemorrhage
Primary: Cerebral Artery Vasospasm — 16; 7 Participants
Phase 2 N=56 Effect of Red Blood Cell Transfusion on Brain Metabolism in Patients With Subarachnoid Hemorrhage
Subarachnoid Hemorrhage · Vasospasm
Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001
Phase 2 N=59 The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
Aneurysmal Subarachnoid Hemorrhage
Primary: Cerebrospinal Fluid 3-aminopropanal (CSF-3AP) Levels — 11.1; 12.9 nmol/mL
N/A N=34 Preconditioning for Aneurismal Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
Primary: Number of Patients With Deep Vein Thrombosis for Safety Assessment. — 0; 3; 0; 0 participants
N/A N=84 Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH
Subarachnoid Hemorrhage
Primary: In-hospital Seizures — 3; 1 Participants
Phase 2 N=10 Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage
Cerebral Vasospasm After Subarachnoid Hemorrhage
Primary: Hemodynamic Parameters (Change From Baseline Systolic Blood Pressure (Pre-infusion) Over Time Until 135 Minutes Post-infusion) — -8; -3.4 mmHg
Phase 2 N=185 Evaluating Neuroprotection in Aneurysm Coiling Therapy
Stroke
Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445
N/A N=213 Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms
Brain Aneurysm
Primary: mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any…
N/A N=40 Safety and Efficacy of Non-invasive Vagus Nerve Stimulation in the Treatment of Headache in Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Aneurysmal
Primary: The Difference Between the Active and Sham Treatment Groups in Morphine Equivalence Dosage PER DAY — 0.058; 0.24 mg
Phase 2 N=92 The Spot Sign for Predicting and Treating ICH Growth Study
Intracerebral Hemorrhage
Primary: Number of Study Subjects With Life-threatening Thromboembolic Complications — 1; 0; 0 Participants — p=1.00
Phase 2 N=36 Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…
Phase 1 N=60 Antihypertensive Treatment in Acute Cerebral Hemorrhage
Intracerebral Hemorrhage · Hypertension · Stroke
Primary: Particpants Who Achieve and Maintain the Systolic Blood Pressure Goals for Each Treatment Tier. — 18; 20; 22; 7 participants — p=< 0.01
N/A N=30 Vesalio NeVa VS for Symptomatic Cerebral Vasospasm Following aSAH (The VITAL Study)
Cerebral Vasospasm
Primary: Procedural Success — 64 Vessels Treated
Phase 2 N=19 Safety and Pharmacokinetic Evaluation of Nitrite for Prevention of Cerebral Vasospasm
Subarachnoid Hemorrhage
Primary: Mean Plasma Nitrite Concentration (Micromol/L) — 4.2; 4.3; 2.6 micromol/L
N/A N=376 Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
Chronic Subdural Hematoma
Primary: Residual or Re-accumulation of the Chronic Subdural Hematoma (cSDH) (Greater Than [>] 10 Millimeter [mm]) as Assessed by an Independent Core Laboratory OR Any…
N/A N=123 CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
CCM · Cavernoma · Cerebral Cavernous Malformation
Primary: Rate of Recurrent Symptomatic Hemorrhage During the Two Year Follow-up Period in Patients With CASH. — 10; 11 Number of new bleeds
Phase 3 N=499 Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
Intracerebral Hemorrhage
Primary: Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted) — 110; 100; 139; 140 Participants — p=0.73
N/A N=38 INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage
Intracranial Hemorrhage
Primary: Number of Participants With Modified Rankin Score (mRS) ≤ 3 or mRS > 3 — 17; 20 Participants
N/A N=197 Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device
Intracranial Aneurysm
Primary: The Percentage of Participants With the Occurrence of Major Stroke in the Territory Supplied by the Treated Artery or Neurological Death at 12-Months Post Procedure…
N/A N=132 Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
Intracranial Aneurysm
Primary: Prognostic Value of the MAFA (Mean Aneurysm Flow Amplitude) Ratio With Respect to Full Aneurysm Occlusion Within 12 Months — 0.540 probability
N/A N=672 Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas
Head Trauma · Craniocerebral Injuries · Crushing Skull Injury
Primary: Number of Participants With Detection of Hematoma Stratified by CT Positive and CT Negative Status — 158; 22; 126; 81 Participants
Phase 4 N=82 Seizure Prophylaxis in Aneurysm Repair
Intracranial Aneurysms · Seizure
Primary: Incidence of Seizure — 2; 1; 0; 0 Participants